Table 1.
Distribution of clinical and surgical characteristics by percent fall in CA-125 levels after neoadjuvant chemotherapy (n=406)
| Variable | R > 95 (n=230), n (%) | R < 95 (n=176), n (%) | P |
|---|---|---|---|
| Age (median), years | 50 (45-54) | 53 (40-63) | 0.62 |
| Histology | |||
| Serous | 218 (94.7) | 170 (96.5) | 0.77 |
| Endometrioid | 8 (3.4) | 4 (2.2) | |
| Clear cell | 3 (1.3) | 1 (0.5) | |
| Others | 1 (0.4) | 1 (0.5) | |
| Stage | |||
| III | 156 (67.8) | 118 (67) | 0.57 |
| IV | 74 (32.1) | 58 (33) | |
| Grade | |||
| High grade | 103 (44.7) | 68 (38.6) | 0.91 |
| Not specified | 127 (55.2) | 108 (61.3) | |
| Preoperative fall in CA-125 levels (median) | 97.9 | 87.3 | 0.00 |
| Preoperative CA-125 levels (median) U/ml | 24 | 107 | 0.00 |
| Extent of cytoreduction | |||
| Complete | 152 (66) | 52 (59.5) | 0.00 |
| Optimal | 51 (22.1) | 18 (10.2) | |
| Suboptimal | 24 (10) | 93 (52.8) | |
| Inoperable | 03 (1.3) | 13 (7.3) | |
| Bowel and upper abdominal surgeries | 20 (8.6) | 09 (5.1) | 0.69 |
| Number of NACT cycles | |||
| <3 | 143 (62.1) | 110 (62.5) | 1.0 |
| ≥3 | 87 (37.8) | 66 (37.5) |
NACT=Neo-adjuvant chemotherapy